Abstract | OBJECTIVES: METHODS: We retrospectively evaluated the safety and efficacy of DQS in 10 patients with mild to moderate cGVHD-induced DED. The efficacy was assessed by (1) degree of symptoms, (2) Schirmer I test value, (3) tear film breakup time (TFBUT), and (4) fluorescein and rose bengal scores. RESULTS: The median duration of DQS treatment was 12.0 months (range 6-17 months). DQS was effective for relieving severe pain caused by cGVHD-related DED. Although the Schirmer I test value was enhanced only marginally, the long-term application of DQS significantly improved the corneal/conjunctival epitheliopathy and tear film stability: the fluorescein score improved from 5.9±0.6 to 1.3±1.1 points (P=1.771×10); rose bengal staining from 4.7±1.6 to 2.0±1.5 points (P=0.008); and TFBUT from 2.6±0.9 to 4.6±1.6 mm (P=0.009). Furthermore, the long-term DQS treatment caused no major adverse events. CONCLUSIONS: This study suggested that long-term DQS treatment is a safe and robust approach for alleviating cGVHD-related DED.
|
Authors | Mio Yamane, Yoko Ogawa, Masaki Fukui, Mizuka Kamoi, Miki Uchino, Yumiko Saijo-Ban, Naoyuki Kozuki, Shin Mukai, Takehiko Mori, Shinichiro Okamoto, Kazuo Tsubota |
Journal | Eye & contact lens
(Eye Contact Lens)
Vol. 44 Suppl 2
Pg. S215-S220
(Nov 2018)
ISSN: 1542-233X [Electronic] United States |
PMID | 29280750
(Publication Type: Journal Article)
|
Chemical References |
- Mucins
- Ophthalmic Solutions
- Polyphosphates
- Uracil Nucleotides
- diquafosol
|
Topics |
- Adult
- Aged
- Conjunctiva
(metabolism)
- Cornea
(metabolism, pathology)
- Dry Eye Syndromes
(drug therapy, etiology, physiopathology)
- Female
- Graft vs Host Disease
(complications)
- Humans
- Male
- Middle Aged
- Mucins
(metabolism)
- Ophthalmic Solutions
(administration & dosage)
- Polyphosphates
(administration & dosage)
- Retrospective Studies
- Tears
(metabolism)
- Uracil Nucleotides
(administration & dosage)
|